AOD-9604 (2mg)

AOD-9604 mimics the fat-reducing activity of hGH while minimizing anabolic or diabetogenic effects. Unlike hGH, it does not significantly interact with the GH receptor, which limits its influence on insulin resistance, blood sugar levels, or tissue growth.

Its mechanism centers on:

• Enhancing fat breakdown (lipolysis)
• Blocking fat formation (lipogenesis)
• Targeting adipose tissue metabolism without stimulating IGF-1 release or altering blood glucose significantly.

These characteristics make AOD-9604 particularly attractive for studies investigating fat loss and metabolic regulation, especially in populations where full hGH treatment would be contraindicated.

• Animal studies demonstrated significant reductions in adipose tissue without impacting blood glucose or IGF-1 levels.
• Human clinical trials showed a favorable safety profile and mild weight reduction in overweight individuals, though the compound was not approved for obesity treatment by regulatory agencies.
• Some exploratory have evaluated AOD-9604 for osteoarthritis and cartilage regeneration due to its potential tissue-repair properties.
  

• Peptide Type: Fragment of hGH (residues 176–191)
• Administration: Typically administered via subcutaneous injection
• Half-life: Short, with effects achieved through cumulative activity
• Safety: Well-tolerated in clinical settings; non-toxic in approved dosing ranges; minimal to no effect on IGF-1 levels

• The information provided on this site is intended exclusively for educational and research purposes and should not be interpreted as medical guidance.
• Research compounds, including AOD-9604, are designed solely for laboratory investigation by qualified professionals and are not intended for human use or consumption.
• The statements presented here have not been evaluated by the U.S. Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease.